Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
2 April 2024 |
Main ID: |
EUCTR2015-001870-16-DE |
Date of registration:
|
28/10/2015 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
An extension study for patients with Spinal Muscular Atrophy who participated to the previous ISIS 396443 studies
|
Scientific title:
|
An Open-label Extension Study for Patients with Spinal Muscular Atrophy who Previously Participated in Investigational Studies of ISIS 396443 |
Date of first enrolment:
|
08/03/2016 |
Target sample size:
|
292 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001870-16 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: yes Other trial design description: The study is an open label extension If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 1
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Australia
|
Belgium
|
Canada
|
France
|
Germany
|
Hong Kong
|
Italy
|
Japan
|
Korea, Republic of
|
Spain
|
Sweden
|
Turkey
|
United Kingdom
|
United States
| | |
Contacts
|
Name:
|
Medical Director
|
Address:
|
Innovation House, 70 Norden Road
SL6 4AY
Maidenhead
United Kingdom |
Telephone:
|
|
Email:
|
clinicaltrials@biogen.com |
Affiliation:
|
Biogen |
|
Name:
|
Medical Director
|
Address:
|
Innovation House, 70 Norden Road
SL6 4AY
Maidenhead
United Kingdom |
Telephone:
|
|
Email:
|
clinicaltrials@biogen.com |
Affiliation:
|
Biogen |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Subjects must meet all of the following criteria at Screening to be eligible: 1. Signed informed consent of parent or guardian and signed informed assent of subject, if indicated per subject's age and institutional guidelines. 2. Completion of the index study in accordance with the study protocol or as a result of Sponsor decision (e.g., early termination of the index study) within the preceding 16 weeks. Are the trial subjects under 18? yes Number of subjects for this age range: 278 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 14 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria: Subjects meeting any of the following criteria are not eligible for the study: - Have any condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study - Clinically significant abnormalities in hematology or clinical chemistry parameters or electrocardiogramm (ECG), as assessed by the Site Investigator, at the Screening visit that would render the participant unsuitable for participation in the study - Participant’s parent or legal guardian is not willing or able to meet standard of care guidelines (including vaccinations and respiratory syncytial virus prophylaxis if available), nor provide nutritional and respiratory support throughout the study - Treatment with another investigational agent, biological agent, or device within one month of Screening, or 5 half-lives of study agent, whichever is longer NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Spinal Muscular Atrophy (SMA) MedDRA version: 20.1
Level: PT
Classification code 10041582
Term: Spinal muscular atrophy
System Organ Class: 10010331 - Congenital, familial and genetic disorders
|
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
|
Intervention(s)
|
Trade Name: Spinraza Product Name: Survival of Motor Neuron 2 (SMN2) Splicing Modulator Antisense Oligonucleotide Product Code: ISIS 396443 Pharmaceutical Form: Solution for injection INN or Proposed INN: Nusinersen CAS Number: 1258984-36-9 Current Sponsor code: ISIS 396443 (BIIB058) Other descriptive name: ISIS 396443 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2.4-
|
Primary Outcome(s)
|
Main Objective: To evaluate the long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to subjects with SMA who previously participated in investigational studies of nusinersen.
|
Primary end point(s): - Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs) - Number of participants with clinically significant vital sign abnormalities - Number of participants with clinically significant weight abnormalities - Number of participants with clinically significant neurological examination abnormalities - Number of participants with clinically significant laboratory assessment abnormalities - Number of participants with clinically significant coagulation parameter abnormalities - Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities - Change from Baseline in concomitant medications
|
Secondary Objective: To examine the long-term efficacy of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to subjects with SMA who previously participated in investigational studies of nusinersen.
|
Timepoint(s) of evaluation of this end point: Up to Day 1814
|
Secondary Outcome(s)
|
Secondary end point(s): - Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria - Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE) - Time to death or permanent ventilation - Percentage of participants not requiring permanent ventilation - Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale - Change from Baseline in Hammersmith Functional Motor Scale - Change from Baseline in Revised Upper Limb Module (RULM) - Change from Baseline in 6-Minute Walk Test (6MWT) - Change from Baseline in Compound Muscular Action Potential (CMAP) - Change from Baseline in body length and/or height (for all participants) - Change from Baseline in head circumference (for participants up to 36 months of age) - Change from Baseline in chest circumference (for participants up to 36 months of age) - Change from Baseline in arm circumference (for participants up to 36 months of age) - Proportion of CMAP responders - Number of participants with motor milestones achieved - Proportion of participants who achieved standing alone - Proportion of participants who achieved walking with assistance - Number of participants with serious respiratory events - Number of participants hospitalized - Duration of hospitalizations - Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine - Change from Baseline in Quality of Life (QOL) Questionnaires - Number of Disease-related hospitalizations and AEs - Overall survival rate
|
Timepoint(s) of evaluation of this end point: Up to Day 1814
|
Secondary ID(s)
|
NCT02386553
|
110011
|
ISIS396443-CS11
|
Source(s) of Monetary Support
|
Biogen Idec Research Limited
|
Ethics review
|
Status: Approved
Approval date: 08/03/2016
Contact:
|
|